Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Investor Update
Get the latest updates from Investor Update directly as they happen.
Follow now 571 followers
Latest posts
Last updated about 13 hours ago
European Commission approves Roche’s Susvimo® for the treatment of neovascular age-related macular degeneration (nAMD)
about 13 hours ago
By continuously delivering medicine into the eye through the Contivue refillable implant...
Reminder: Invitation to Roche Pharma Day 2026
4 days ago
The Roche Investor Relations team would like to invite you to the...
Roche’s Lunsumio-based regimen significantly improves progression-free survival in follicular lymphoma in phase III CELESTIMO study
5 days ago
Phase III CELESTIMO study met its primary endpoint at the interim analysis...
Roche’s collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancer
9 days ago
Tambotatug pelitecan (Tam-Peli) demonstrated statistically significant efficacy over topotecan in a phase...
U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatments
12 days ago
If approved, Enspryng would be the first and only disease-modifying therapy for...
Reminder: Invitation to Roche Pharma Day 2026
19 days ago
The Roche Investor Relations team would like to invite you to the...
Roche receives FDA clearance for Elecsys® pTau217, advancing Alzheimer’s disease assessment across primary and specialty care
29 days ago
First and only FDA-cleared, single-biomarker blood test supporting both rule-in and rule-out...
Invitation to Roche Pharma Day 2026
about 1 month ago
The Roche Investor Relations team would like to invite you to the...
Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
about 2 months ago
Dear Investor, Please find attached a press release from our partner Nurix...
CHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD)
about 2 months ago
Susvimo is the first and only continuous delivery treatment that offers an...
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc
2 months ago
Group sales were +6% at constant exchange rates (CER)1, -2% when reported...
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc
2 months ago
Group sales were +6% at constant exchange rates (CER)1, -2% when reported...